Event Partner

Keynote Presentations

WORLD'S FIRST EGG-FREE INFLUENZA VACCINE
Manon M.J. Cox, Ph.D., President and CEO, Protein Sciences Corporation

CELL CULTURE-BASED VACCINES
Rino Rappuoli, Ph.D., Global Head, Vaccines Research, Novartis Vaccines & Diagnostics, Italy

NEW INFLUENZA VACCINES FOR PANDEMIC PREPAREDNESS
Robert C. Huebner, Ph.D., Acting Director Influenza Division, HHS/ASPR/BARDA

WHAT'S HAPPENING ON THE VACCINE ADJUVANT FRONT?
Nikolai Petrovsky, Ph.D., Endocrinology Department, Flinders Medical Centre, Australia

Bonus: 2 Conference for the Price of 1

Attend IBC's co-located Single-Use Applications for Biopharmaceutical Manufacturing at no extra change

Present a Poster

Do you have new data to share? Enhance your conference experience by presenting a poster - it could lead to exciting opportunities for your company.

» Submit your proposal

Get Up To Date Event Information

Join our priority contact list and receive the latest event news.

International speakers from companies including:

• Merck & Co.
• Pfizer
• Lonza
• Novartis Vaccines & Diagnostics
• Pharmajet, Inc.
• NasVax Ltd.
• CBER, FDA
• GlaxoSmithKline Vaccines
• NanoBio Corporation
• Protein Sciences Corporation
• Sanofi Pasteur
• Novavax
• Immune Targeting Systems Ltd.
• Matrivax R&D Corporation
• CureVac GmbH

At this year's event...

• See Who You Can Meet
• Get a Preview of the Onsite Event Guide

Event Overview

IBC's 4th Annual Vaccine Development & Production Summit brings you the newest data on ways to improve yield and reduce cost in vaccine production. Hear discussions on novel, creative strategies such as alternative cell lines, QbD for process control and validation, novel adjuvants and new delivery concepts. Gain insight on continuous improvements in upstream and downstream processing to purify viruses and increase yield.

Exclusive Interview

Exclusive Interview with Manon M.J. Cox, President and CEO, Protein Sciences Corporation
Protein Sciences Corporation developed the world's first recombinant, highly purified, egg-free influenza vaccine, Flublok®, which the FDA regards as a technological advance in the manufacturing of an influenza vaccine.

Improve Yield and Reduce Cost in Vaccine Production

• Discover All Aspects of Development Through the Latest Research on Novel Adjuvants and Innovative Delivery Systems
• Enhance Your Process with Cutting-Edge Formulation Strategies
• Optimize Immune Response and Stability Through New Vaccine Research
• Hear Case Studies and Unpublished Data from Life Science Leaders - GlaxoSmithKline Vaccines, Merck & Co., NasVax Ltd., Novartis Vaccines & Diagnostics, Novavax, Pfizer Inc., Protein Sciences Corp., Sanofi Pasteur - and 17 Other Thought-Leaders on Vaccine Development and Production

New Sessions, More Case Studies and New, Unpublished Data

• New Research on Novel Adjuvants
• Case Study: Single-Use Technology Deployment for Anthrax Vaccine Production
• Needleless Vaccine Delivery
• Vaccine Formulation and Analytical Challenges
• Insect Cell-Based Vaccine Production
• Cost and Quality Considerations for Plant-Based Production Systems
• Quality-by-Design Implementation for Vaccine Production
• Protein Capsular Matrix Vaccine Technology

Learn All Aspects of Development

Throughout our research for this conference it was clear that the many aspects of development are crucial right now. That's why this year's program has an emphasis on these issues. Hear about process improvements that use QbD, the process modernization of an anthrax vaccine with single-use technologies, as well as novel formulation with insect cell-based cultures and needle-free delivery.

Stay Ahead of Your Competition

This conference gives you the opportunity to learn what industry leaders are doing to stay competitive in the surging vaccines market. You will learn how to enhance your process and improve yield, while reducing costs. Delve into novel (and needleless) vaccine delivery platforms. Gain applicable knowledge from case studies on process development and manufacturing challenges, and quality-by-design implementation. Discover how single-use deployment can modify your production process and increase throughput.